Skip to content

Intraoperative Endovascular Treatment Via the Ligamentum Teres Hepatis in Liver Transplantation for Yerdel Grade Ⅲ/IV Portal Vein Thrombosis: A Safe and Effective Strategy

Intraoperative Endovascular Treatment Via the Ligamentum Teres Hepatis in Liver Transplantation for Yerdel Grade Ⅲ/IV Portal Vein Thrombosis: A Safe and Effective Strategy

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07192653
Enrollment
75
Registered
2025-09-25
Start date
2016-02-29
Completion date
2025-04-30
Last updated
2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endovascular Treatment, Liver Transplantation

Brief summary

Background: To evaluate the safety and efficacy of intraoperative endovascular treatment (EVT) using the donor ligamentum teres hepatis (LTH) approach for Yerdel grade III/IV portal vein thrombosis (PVT) during liver transplantation (LT), a condition that poses a major challenge in complex surgeries. Methods: This single-center retrospective cohort study included some patients with grade III/IV PVT who underwent LT and were divided into two periods: in both periods, patients underwent modified eversion thrombectomy. However, in Period 1 (2016-2019), nonanatomical anastomosis was performed if portal flow was insufficient, and in Period 2 (2019-2024), patients with persistent hypoperfusion underwent additional LTH-based EVT (stenting or shunt occlusion). Perioperative outcomes (operative time, anhepatic phase, and anastomosis type) and long-term outcomes (graft survival and complication rates) were compared between groups.

Interventions

PROCEDUREnonanatomical anastomosis

In Period 1 (2016-2019, n=41), nonanatomical anastomosis was performed if portal flow was insufficient.

PROCEDURELTH-based EVT

In Period 2 (2019-2024, n=34), patients with persistent hypoperfusion underwent additional LTH-based EVT (stenting or shunt occlusion)

Sponsors

Chiyi Chen
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients (aged ≥18 years). * Patients underwent deceased-donor liver transplantation. * At Tianjin First Central Hospital between February 2016 and December 2024. * Identified recipients with Yerdel grade III/IV PVT, which was confirmed by multiphase contrast-enhanced CT, indirect portography, and intraoperative evaluation

Exclusion criteria

*

Design outcomes

Primary

MeasureTime frameDescription
Operative TimeIntraoperativeOperative time refers to the duration from the initial surgical incision to the completion of skin closure.
Anhepatic Phase TimeIntraoperativeThe anhepatic phase time is the critical period during liver transplant surgery when the patient's native liver has been removed and the donor liver has not yet been reperfused.
Rate of Nonanatomical ReconstructionIntraoperativeThe rate of nonanatomical resection refers to the frequency with which a surgical procedure removes a tumor without following the boundaries of the organ's functional anatomical units.
Delayed Graft FunctionWithin 7 days postoperativelyDelayed graft function is a common complication following kidney transplantation where the transplanted organ does not function immediately, often necessitating dialysis within the first week post-surgery.
Portal Vein ComplicationsFrom the surgery to the last follow-up (median follow-up 28 months)Portal vein complications are a serious concern in liver transplantation, encompassing issues such as thrombosis, stenosis, and occlusion that can threaten graft survival and patient life.
Graft Survival1-year and 3-year postoperativelyGraft survival refers to the continued functional existence of a transplanted organ or tissue within a recipient's body.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026